Chardan Capital Reiterates Buy on Outlook Therapeutics, Maintains $10 Price Target
Portfolio Pulse from richadhand@benzinga.com
Chardan Capital analyst Daniil Gataulin has reiterated a 'Buy' rating on Outlook Therapeutics (NASDAQ:OTLK) and maintained a $10 price target.
August 15, 2023 | 8:25 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Outlook Therapeutics' stock rating has been reiterated as 'Buy' by Chardan Capital, with a maintained price target of $10.
The reiteration of a 'Buy' rating by a financial analyst usually indicates a positive outlook for the company's stock. The maintained price target of $10 also suggests that the analyst believes the stock is undervalued at its current price, which could lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100